Teprotumumab for Thyroid-Associated Ophthalmopathy.
Teprotumumab is a monoclonal antibody against the IGF-I receptor (IGF-IR) and this early trial in moderate to severe Graves' ophthalmopathy (GO) has shown the remarkable finding of a reduction in the proptosis with the investigated drug compared to placebo. We've had to rely on glucocorticoids and radiotherapy for GO, and while these drugs can calm down the inflammation they were not great at reducing the proptosis, once it had become established.
The potential reduction in proptosis is interesting, and there was also a reduction in clinical activity score. However it's a small trial, for one year only, and it is placebo controlled; it is reasonable to consider how good teprotumumab might be against glucocorticoids +/- radiotherapy, how it might do in the longer term and whether it might prevent GO becoming moderate to severe.
Please do comment and/ or share.
Teprotumumab for Thyroid Eye Disease